Approaches to Patient Eligibility and Administration Timing for Nadofaragene Firadenovec - Alberto Martini
Alberto Martini
Zachary Klaassen hosts Alberto Martini to discuss optimizing patient selection for nadofaragene firadenovec, a gene therapy for BCG-unresponsive bladder cancer.
Metachronous mHSPC Treatment: Role of Darolutamide in Doublet Therapy - Jason Hafron
Jason Hafron
Zachary Klaassen and Jason Hafron examine a case-based approach to metachronous metastatic hormone-sensitive prostate cancer using a 52-year-old patient with BRCA2 mutation who developed oligometastatic disease after failed surgery and salvage radiation.
